A Positive Antibody Screen Delayed Her Surgery by Six Hours

Rosa, a composite patient, was waiting for surgery when the schedule changed. Her operation would start about six hours later than planned because the blood bank needed additional testing.

The line she kept reopening on her patient portal said: “Antibody screen: positive.”

She already knew her blood type. A nurse had confirmed it during the preoperative visit, and Rosa had seen the same type recorded during a pregnancy years earlier. The portal result seemed to contradict that familiar label. She wondered whether the earlier tests had been wrong, whether “positive” meant an infection, and whether the hospital had found something dangerous that no one had explained.

None of those conclusions followed from the line on the screen.

A positive antibody screen usually means the laboratory detected one or more proteins in the patient’s plasma that may react with particular features on donated red blood cells. Plasma is the liquid portion of blood. The proteins, called antibodies, can make finding compatible donor blood more involved than matching the large blood-type categories printed on a card.

The familiar blood-type label is only the beginning

For a red blood cell transfusion, the blood bank first determines the patient’s ABO group and RhD type. ABO refers to the main blood groups A, B, AB, and O. RhD is the feature described by the words positive or negative in a blood type, such as A positive or O negative.

These labels describe antigens, which are markers on the surface of red blood cells. A person with type A blood has the A antigen. Someone with type B has the B antigen. Type AB has both, while type O has neither A nor B.

The immune system can treat an unfamiliar antigen as a target. That is why a major ABO mismatch can be so dangerous: antibodies already present in the recipient’s plasma may attack the transfused cells, breaking them apart and setting off a reaction that can affect blood pressure, the kidneys, and the body’s ability to control bleeding.

ABO and RhD are not the only red-cell antigens. There are hundreds of others, grouped into several blood-group systems, and most never cause a problem for a particular patient. A person may lack one of these antigens yet have an antibody that recognizes it, which means a donor unit carrying that antigen may not be suitable even when its ABO and RhD label appears compatible.

That was the gap between Rosa’s known blood type and the portal line. Her blood type had not changed. The screen had found something beyond the familiar label.

What the blood bank was doing during the delay

A pretransfusion test is often described as a “type and screen.” The type identifies ABO and RhD. The screen mixes the patient’s plasma with selected test cells to look for unexpected red-cell antibodies, meaning antibodies other than the expected ABO antibodies.

A negative screen usually allows the blood bank to move ahead quickly, although staff still complete required identity and compatibility checks. A positive screen opens another stage. Laboratory professionals test the plasma against a larger panel of red cells whose antigens are known, looking at the pattern of reactions to work out which antibody may be present.

That pattern can be straightforward. It can also be faint, involve more than one antibody, or be complicated by a recent transfusion, because donor red cells may still be circulating alongside the patient’s own cells. Some samples need repeat methods or testing at a specialized reference laboratory, which can extend the wait well beyond the six hours Rosa experienced.

Once the likely antibody is identified, staff look for donated red blood cells that do not carry the corresponding antigen. Those units may already be in the hospital, or they may need to come from another blood supplier. Labels are reviewed, selected cells may be tested, and the patient’s plasma is checked against samples from the donor units.

That last check is the crossmatch. It is a final laboratory test of whether the patient’s plasma reacts with the red cells from a particular unit, rather than a promise that every possible transfusion reaction has been eliminated.

Rosa’s operation was expected to involve enough blood loss that the surgical and anesthesia teams wanted compatible units available before proceeding. The delay did not mean she was already having a transfusion reaction. No donor blood had entered her body. It meant the hospital did not want to begin until the blood bank had units ready if they were needed.

Where red-cell antibodies come from

Some red-cell antibodies develop after the immune system encounters blood cells with antigens it does not recognize. Pregnancy can provide that exposure because fetal red blood cells may carry antigens inherited from the other biological parent. A previous transfusion can do the same.

Rosa’s earlier pregnancy was one possible explanation, but the portal line alone could not establish the cause. Some antibodies arise without a known transfusion or pregnancy exposure, and a person may have no memory of being told about an antibody found many years earlier.

The amount of an antibody in the blood can also fall until a current screening test barely detects it or does not detect it at all. The immune system may still remember the antigen and produce the antibody again after another exposure. Blood banks therefore pay attention to a documented antibody history, even when a later screen appears negative.

A positive antibody screen does not, by itself, mean a person has an autoimmune disease, an infection, or an allergy. It also does not show whether an antibody is likely to damage transfused cells. Identification matters because different antibodies behave differently, and laboratory staff interpret the result alongside transfusion history and other testing.

What can happen when incompatible blood is transfused

The most feared mismatch involves ABO-incompatible red blood cells. The recipient’s antibodies can attack those cells rapidly, sometimes while the transfusion is still running. Possible signs include fever, chills, pain, low blood pressure, breathing problems, dark urine, bleeding, or kidney injury. A severe reaction can be fatal.

Other antibodies may cause a delayed hemolytic transfusion reaction. Hemolysis means the destruction of red blood cells. In a delayed reaction, transfused cells are removed from circulation over days or weeks, and the change may first appear as a falling hemoglobin level, jaundice, fatigue, or an unexpected lack of benefit from the transfusion.

Compatibility testing is designed to reduce these risks before a unit reaches the bedside. Staff also confirm the patient’s identity, compare the blood order with the unit, and monitor the person during transfusion. A mislabeled sample can undermine even sophisticated testing, so some hospitals require a second independently collected specimen when there is no confirmed historical blood type.

The word “compatible” still has limits. People can react to transfusions for reasons unrelated to red-cell antigen matching, and no laboratory check can predict every response. The practical goal is to avoid known incompatibilities while making blood available within the time the person’s condition allows.

Why the hospital did not just use O-negative blood

O-negative red blood cells lack A, B, and RhD antigens, which makes them useful when a patient’s ABO type is unknown or there is no time for full testing. They still carry many other red-cell antigens. If a patient has an antibody against one of those antigens, an O-negative unit may remain incompatible.

O-negative blood is also limited. Hospitals often preserve it for patients who are most likely to need RhD-negative emergency blood, while using other emergency-release options when clinically appropriate. The choice depends on the patient, the available inventory, the urgency, and the type of blood component being given.

In a life-threatening emergency, clinicians may release blood before every compatibility test is complete. That decision weighs the immediate danger of waiting against the possibility of a reaction, and the blood bank continues testing while care proceeds. Rosa’s operation was important but planned, so her team had time to wait for antigen-negative, crossmatched units.

Six hours after she first saw the portal result, the schedule moved again. The blood bank had located suitable units and completed the checks requested for surgery. The line “Antibody screen: positive” remained on the screen, but it no longer looked like a verdict. It described the reason for the pause.

What this explanation cannot tell you

A portal result cannot reveal which antibody was found, how clinically significant it was, how many compatible units were available, or how long another patient’s testing might take. This piece cannot interpret an individual laboratory result or explain whether a particular operation can proceed without blood on hand.

The surgeon and anesthesia professional can explain how blood availability affects an operation. The hospital care team can obtain the blood bank’s interpretation, including the antibody’s name and whether it should remain in the transfusion history for future care.

Questions people ask

Does a positive antibody screen mean my blood type is wrong?

Usually, no. ABO and RhD typing identifies the familiar blood label, while the antibody screen looks for reactions involving other red-cell antigens. In Rosa’s case, the recorded blood type stayed the same; the positive screen added information the blood bank needed before selecting donor units.

Why can’t the hospital give everyone O-negative blood?

O-negative red blood cells avoid A, B, and RhD mismatches, but they carry other antigens that can react with a patient’s antibodies. Supplies are also limited. Hospitals reserve and select units according to urgency, inventory, patient characteristics, and the compatibility information available at that moment.

Can surgery proceed before matching is finished?

Sometimes blood is released before testing is complete when waiting would create a greater immediate danger. For a planned operation, the surgical and anesthesia teams may delay until compatible units are available, especially when meaningful blood loss is expected. Rosa’s team chose that route, and her surgery began about six hours later.

Will the antibody matter during a future transfusion?

It may. Some antibodies become too weak to detect but remain important because the immune system can respond again after exposure. Blood banks often retain a history of previously identified antibodies, so Rosa’s result did not disappear when surgery ended; the antibody’s name remained in her transfusion record beside the original portal result.